Insight Molecular Diagnostics Inc. underwent a corporate name change from its former identity as Oncocyte Corporation, executing the transition via a corporate restructuring and filing official documents with regulatory authorities. Alongside this organizational rebranding, the company updated its Nasdaq stock ticker symbol to IMDX to better align its public market presence with its evolving strategic focus on molecular diagnostics and precision oncology testing.